Ellis AK, et al. - Researchers performed a cost-minimization analysis determining the economic implications of the introduction of the SQ house dust mite sublingual immunotherapy (SQ HDM SLIT)-tablet marketed as ACARIZAX (regulatory approval May 2017) for the treatment of HDM-induced allergic rhinitis in Canada (Ontario and Quebec), where house dust mite subcutaneous immunotherapy (HDM SCIT) is already an available treatment option. For a 3-year treatment with SQ HDM SLIT-tablets, they noted higher direct treatment costs than for HDM SCIT for both provinces, Ontario and Quebec ($4732.12 and $4829.03 vs $3434.51 and $2987.74). However, when the indirect costs were added to the model, they noted total savings for the treatment with SQ HDM SLIT-tablets of $1833.00 for Ontario and $769.03 for Quebec. They identified savings of SQ HDM SLIT-tablets over HDM SCIT in all scenarios analyzed in sensitivity analyses with varying HDM SCIT resource use, discount rates, titration and maintenance injections, nurse time, and number of injections per vial resulted. Hence, when considered from a societal perspective, SQ HDM SLIT-tablets seems a cost-minimizing alternative to HDM SCIT in Ontario and Quebec.